Scienture Holdings, Inc. Price & Performance (SCNX)

Scienture Holdings has secured FDA approval for Arbli™, the first ready-to-use oral liquid losartan in the U.S. The drug targets hypertension, stroke risk, and diabetic nephropathy. The company plans a Q3 2025 launch, leveraging an Equity Line of Credit to fund commercialization efforts while pausing further draws to stabilize its stock.12

In a collaboration with Kindeva, Scienture Holdings will launch REZENOPY®, a 10mg naloxone nasal spray for opioid overdoses. As the highest-strength naloxone available, it addresses a critical need in combating synthetic opioids. This move aligns with the company’s strategy to provide innovative treatments for unmet medical needs.34

Scienture Holdings' shares have seen significant fluctuations, hitting all-time lows recently. This comes amidst news of FDA approvals and strategic moves, including the planned launch of Arbli™ and REZENOPY®. Investors remain cautious as the company navigates financial challenges and prepares for major product rollouts.56